Trial ID 21346 | Maryland Oncology Hematology Trial ID 21346 – Maryland Oncology Hematology

Trial ID 21346

Trial Information - Phase I

An Open-Label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics and Maximum Tolerated Dose of VIP152 (BAY 1251152) as monotherapy or in combination with KEYTRUDA® (pembrolizumab) in Subjects with Advanced Cancer

Protocol ID: VNC-152-101

Sponsor: Vincerx Pharma, Inc.

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Lymphoma

Investigator

Aylesworth MD, Cheryl

Status

OPEN TO ENROLLMENT

Sponsor

Vincerx Pharma, Inc.

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology